{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:14:08Z","timestamp":1788783248672,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST109-2314-B-002-233-MY3"],"award-info":[{"award-number":["MOST109-2314-B-002-233-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NTUCCS-111-19"],"award-info":[{"award-number":["NTUCCS-111-19"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NTUCCS-109-06"],"award-info":[{"award-number":["NTUCCS-109-06"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.canlet.2023.216063","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T13:20:04Z","timestamp":1674048004000},"page":"216063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma"],"prefix":"10.1016","volume":"556","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0349-9180","authenticated-orcid":false,"given":"Zhong-Zhe","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickey C-T","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Shen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-An Annie","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiou-Hwei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2023.216063_bib1","year":"2020","journal-title":"GLOBOCAN"},{"key":"10.1016\/j.canlet.2023.216063_bib2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2023.216063_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1159\/000511001","article-title":"Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update","volume":"9","author":"Kudo","year":"2020","journal-title":"Liver Canc"},{"key":"10.1016\/j.canlet.2023.216063_bib4","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2023.216063_bib5","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.ymthe.2021.04.015","article-title":"Beyond cancer cells: targeting the tumor microenvironment with gene therapy and armed oncolytic virus","volume":"29","author":"Wan","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2023.216063_bib6","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.3390\/cancers12123514","article-title":"HSV-1 oncolytic viruses from bench to bedside: an overview of current clinical trials","volume":"12","author":"Koch","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2023.216063_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2023.216063_bib8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/ijc.27770","article-title":"Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice","volume":"132","author":"Lin","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2023.216063_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1078-0432.CCR-1075-3","article-title":"Telomerase-specific replication-selective virotherapy for human cancer","volume":"10","author":"Kawashima","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216063_bib10","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1038\/sj.onc.1203733","article-title":"Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues","volume":"19","author":"Kawakami","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216063_bib11","article-title":"The emerging roles of HDACs and their therapeutic implications in cancer","volume":"932","author":"Hai","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.canlet.2023.216063_bib12","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1158\/1078-0432.CCR-06-0429","article-title":"Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer","volume":"12","author":"Kulp","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216063_bib13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00280-020-04229-3","article-title":"A Phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies","volume":"87","author":"Collier","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2023.216063_bib14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.21804","article-title":"Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma","volume":"46","author":"Lu","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2023.216063_bib15","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.canlet.2023.216063_bib16","first-page":"5394","article-title":"The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells","volume":"9","author":"Goldsmith","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216063_bib17","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.drudis.2022.02.009","article-title":"Histone deacetylase inhibitor-based oncolytic virotherapy: a promising strategy for cancer treatment","volume":"27","author":"Shirbhate","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.canlet.2023.216063_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.canlet.2023.216063_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/1471-2407-10-461","article-title":"Significance of aurora B overexpression in hepatocellular carcinoma","volume":"10","author":"Lin","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2023.216063_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12885-022-09288-8","article-title":"Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma","volume":"22","author":"Shao","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2023.216063_bib21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/mt.2011.276","article-title":"The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers","volume":"20","author":"Parato","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2023.216063_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbrc.2013.04.049","article-title":"Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism","volume":"435","author":"Yang","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2023.216063_bib23","first-page":"183","article-title":"Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy","volume":"4","author":"Nakashima","year":"2015","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/j.canlet.2023.216063_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113986","article-title":"Virotherapy: from single agents to combinatorial treatments","volume":"177","author":"Malfitano","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2023.216063_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/v8010009","article-title":"Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade","volume":"8","author":"Marchini","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.canlet.2023.216063_bib26","first-page":"6328","article-title":"Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228","volume":"61","author":"Kitazono","year":"2001","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2023.216063_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014700","article-title":"The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication","volume":"6","author":"Danielsson","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2023.216063_bib28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/cgt.2012.57","article-title":"Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells","volume":"19","author":"Watanabe","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2023.216063_bib29","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ymthe.2006.07.009","article-title":"Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy","volume":"14","author":"H\u00f6ti","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2023.216063_bib30","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/mt.2008.155","article-title":"Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses","volume":"16","author":"Otsuki","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2023.216063_bib31","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/ijc.26241","article-title":"Histone deacetylase inhibition as an anticancer telomerase-targeting strategy","volume":"129","author":"Rahman","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2023.216063_bib32","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/jcp.25226","article-title":"Differential regulation of telomerase reverse transcriptase promoter activation and protein degradation by histone deacetylase inhibition","volume":"231","author":"Qing","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2023.216063_bib33","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/mt.2011.65","article-title":"Thunder and lightning: immunotherapy and oncolytic viruses collide","volume":"19","author":"Melcher","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2023.216063_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2020.07.002","article-title":"The pros and cons of interferons for oncolytic virotherapy","volume":"56","author":"Geoffroy","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.canlet.2023.216063_bib35","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3892\/ijo.2016.3675","article-title":"Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus","volume":"49","author":"Ellerhoff","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2023.216063_bib36","doi-asserted-by":"crossref","first-page":"14742","DOI":"10.1073\/pnas.2433987100","article-title":"Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1","volume":"100","author":"Nusinzon","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2023.216063_bib37","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2023.216063_bib38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1819","article-title":"Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis","volume":"6","author":"Cully","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2023.216063_bib39","first-page":"729","article-title":"Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy","volume":"34","author":"Ulasov","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2023.216063_bib40","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1128\/JVI.01972-08","article-title":"E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus","volume":"83","author":"Thomas","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2023.216063_bib41","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3892\/or.2014.3020","article-title":"PI3K inhibitor LY294002 inhibits activation of the Akt\/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus","volume":"31","author":"Tong","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2023.216063_bib42","doi-asserted-by":"crossref","first-page":"38879","DOI":"10.1074\/jbc.M505733200","article-title":"Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes","volume":"280","author":"Chen","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2023.216063_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12885-017-3046-6","article-title":"Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis","volume":"17","author":"Murahari","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2023.216063_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.19","article-title":"Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma","volume":"2","author":"Ruf","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2023.216063_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092919","article-title":"Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells","volume":"9","author":"Cody","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2023.216063_bib46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/cgt.2012.89","article-title":"The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells","volume":"20","author":"White","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2023.216063_bib47","first-page":"218","article-title":"Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors","volume":"29","author":"Kim","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.canlet.2023.216063_bib48","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/mt.2008.58","article-title":"Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects","volume":"16","author":"Liu","year":"2008","journal-title":"Mol. Ther."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523000149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523000149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:54:37Z","timestamp":1778684077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":48,"alternative-id":["S0304383523000149"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216063","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216063"}}